CSBio CSBio

X
[{"orgOrder":0,"company":"BioInvent","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"BioInvent Receives \u20ac2 million Milestone from Daiichi Sankyo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"BioInvent"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia IND Application for CAN04 Approved by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Cantargia AB"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Submits Application to Start New Clinical Trial Investigating Antibody CAN04 and FOLFIRINOX in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Cantargia AB"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reaches Recruitment Milestone And Focuses Nadunolimab Development On Upcoming Randomized Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Cantargia AB"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Receives Regulatory Approval from MHRA for Phase 1\/2a Combination Study with MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Medivir"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Birinapant Clinical Study Initiated By IGM Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Medivir"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mendus"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus To Report Positive Clinical And Preclinical Data In Ovarian Cancer At The European Society Of Gynaecological Oncology 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Mendus"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Provides Status Update in the Portfolio Projects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Receive Milestone Payment From Neotx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech: Tasquinimod Clinical Development in Multiple Myeloma Advances Into Combination Therapy Following Completion of The Initial Phase of The Ongoing Trial in The US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data on Naptumomab Estafenatox Enhancing CAR-T Cells Potency Presented by Active Biotech\u2019s Partner NeoTX at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Active Biotech"},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional patients treated in LIDDS clinical study NZ-DTX-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Lidds"},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prostate Cancer Study to Be Initiated at Uppsala University Hospital with Nano Zolid Technology\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Lidds"},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoZolid\u00ae-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Lidds"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"SAKK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Oasmia Pharmaceutical"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oasmia Pharmaceutical"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Increases Focus on Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents Novel Supportive Phase I Data at ASCO for its CTLA-4 x OX40 Bispecific Drug Candidate ATOR-1015","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Receives First Patent Approval for ATOR-1017","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience AB (publ) Interim Report January-June 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents the Clinical Project Portfolio at Virtual R & D Day August 27, 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience: Encouraging Interim Safety Data in Ator-1017 Clinical Phase I Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents Positive Biomarker Data Demonstrating Proof of Mechanism in Mitazalimab Clinical Phase I Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Focuses on ATOR-1017 and Mitazalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expected Therapeutic Dose Levels Achieved in Phase I Study with ATOR-1017","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents at the SITC 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Approved IND for Alligator Bioscience's CD40-Targeting Antibody Mitazalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Submits Cta Application for Mitazalimab Phase II Study OPTIMIZE-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitazalimab Synergizes with Chemotherapy - Alligator Bioscience Presents New Preclinical Data at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            ALG.APV-527 is a bispecific conditional 4-1BB agonist, actuvates upon simultaneous binding to 4-1BB and 5T4. 4-1BB has the ability to stimulate the antitumor-specific T cells and NK cells and 5T4 is an oncofetal tumor associated antigen overexpressed on numerous solid tumors.

            Lead Product(s): ALG.APV-527

            Therapeutic Area: Oncology Product Name: ALG.APV-527

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Aptevo Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The initial data demonstrates that DCP-001, an off-the-shelf intradermal dendritic cell-based vaccine was safe and well-tolerated, confirming the benign safety profile of DCP-001 observed in multiple completed and ongoing clinical trials.

            Lead Product(s): DCP-001

            Therapeutic Area: Oncology Product Name: DCP-001

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The antibody CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. It can counteract contribution of IL-1 system to immune suppressive tumor microenvironment and development of resistance to chemotherapy.

            Lead Product(s): Nadunolimab,Fluorouracil,Calcium Folinate

            Therapeutic Area: Oncology Product Name: CAN04

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ilixadencel (activated allogeneic dendritic cells) is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors, has consistently demonstrated signs of efficacy and maintained a positive safety and tolerability profile.

            Lead Product(s): Activated Allogeneic Dendritic Cells

            Therapeutic Area: Oncology Product Name: Ilixadencel

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply. Oasmia will leverage Lonza’s extensive experience in manufacturing highly-potent API.

            Lead Product(s): Cantrixil

            Therapeutic Area: Oncology Product Name: TRX-E-002-1

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Lonza Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.

            Lead Product(s): Naptumomab Estafenatox,Durvalumab

            Therapeutic Area: Oncology Product Name: ABR-217620

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: NeoTX Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Company initiated its clinical study in solid cancers with birinapant (IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444. The purpose of this first clinical trial with the combination will be to explore safety and tolerability.

            Lead Product(s): Birinapant,IGM-8444

            Therapeutic Area: Oncology Product Name: TL32711

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: IGM Biosciences

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NZ-DTX-001 is intratumoural depot formulation of NanoZolid® in combination with docetaxel for treatment of solid tumors.

            Lead Product(s): NanoZolid-Docetaxel

            Therapeutic Area: Oncology Product Name: NZ-DTX

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 04, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.

            Lead Product(s): Tasquinimod,Ixazomib,Lenalidomide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 03, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In the study, MIV-818 will be administered in two combinations, either with lenvatinib, a tyrosine kinase inhibitor or pembrolizumab, an anti-PD-1 check-point inhibitor.

            Lead Product(s): MIV-818,Lenvatinib

            Therapeutic Area: Oncology Product Name: MIV-818

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY